Wednesday, October 26th, 2022 Session 1: 9am EDT|6am PDT|2pm BST|3pm CEST Session 2: 2pm EDT|11am PDT|7pm BST|8pm CEST Design and intensify a multi-step mAb purification process with limited investment. Lower the complexity barrier to multi-column continuous chromatography.
Register Free: https://www.biopharminternational.com/bp/chromatography
Event Overview:
Biotherapeutics, such as monoclonal antibodies (mAbs) and their modifications, have typically relied on multi-step processes for optimal removal of impurities such as host cell proteins (HCPs), DNA, adventitious viruses, and antibody aggregates. However, additional purification steps increase downstream expenses significantly, including costs of supplementary resin, hardware, buffers, etc. Thus, it is imperative to design and test effective purification procedures for production of high-quality biotherapeutics, but with reasonable production costs, time, and manufacturing space requirements.
Key Learning Objectives:
Who Should Attend:
Speakers
Jukka Kervinen, Ph.D.
Manager, Applications Development
Tosoh Bioscience
Jukka’s industry background is in the development of protein purification processes for monoclonal antibodies, proteolytic enzymes, and vaccine candidates. He currently directs chromatographic method testing for monoclonal antibody, oligonucleotide, and viral vector purification processes and their U/HPLC analysis at Tosoh Bioscience.
Jaclyn Mabry
Applications Scientist – MCC Instruments
Tosoh Bioscience
Jaclyn’s industry background is in the testing of protein purification platforms for monoclonal antibodies by converting known batch purification strategies for use with multi-column continuous chromatography instrumentation. Her current responsibilities at Tosoh Bioscience consist of testing novel uses of their multi-column chromatography instrumentation for the purification development of biopharmaceuticals.
Register Free: https://www.biopharminternational.com/bp/chromatography